CELL ADHESION IN NEOPLASIA AFFECTING HUMAN COMMUNICATION

工作总结： 本项目的目的是阐明黄曲霉毒素的分子机制 细胞黏附和识别是细胞生长和迁移所必需的 上颌鳞状细胞肿瘤中的肿瘤和支持细胞 航空消化道，以开发药理和药物治疗方法 分子预防和治疗。 过度表达的整合素细胞黏附分子谱系 由鳞状细胞癌和形成血管内皮细胞 血管血液供应的特征是免疫生物化学和 免疫组织化学方法。特异性抗体和 这些整合素受体的小分子受体拮抗剂 体外抑制肿瘤细胞和血管内皮细胞的附着和生长 活体内一直是正在进行的研究的主题。附属品 由肿瘤细胞产生的细胞外基质--层粘连蛋白 肿瘤，主要由三种整合素受体引起。 在体外使用特定的抗体。研究以评估这些是否 受体在肿瘤的发展中起着重要作用，并可能适用于 治疗靶点等待小分子抑制剂的开发 这些受体中的每一个。 在使用内皮整合素受体拮抗剂的研究中， 整合素受体家族在肿瘤的生长和发育中起重要作用。 肿瘤诱导新血管生成过程中内皮细胞的迁移。在……里面 初步实验表明，内皮整合素受体拮抗剂 体内发现有抑制鳞状细胞癌生长的作用。进一步 将需要研究以确定最佳配方、剂量和路线 以及在临床试验中使用前的毒性。

Summary of Work: The purpose of this project is to elucidate the molecular mechanisms of cell adhesion and recognition necessary for growth and migration of neoplastic and supporting cells in squamous cell neoplasms of the upper aerodigestive tract in order to develop approaches for pharmacologic and molecular prevention and therapy. A repertoire of integrin cell adhesion molecules that are overexpressed by squamous cell carcinomas and by the endothelial cells that form the vascular blood supply has been characterized by immunobiochemical and immunohistochemical methods. The ability of specific antibodies and small molecule receptor antagonists of these integrin receptors to inhibit attachment and growth of tumor and endothelial cells in vitro and in vivo have been the subject of ongoing investigations. The attachment of tumor cells to laminin, the extracellular matrix produced by the tumors, was shown to be predominantly due to three integrin receptors using specific antibodies in vitro. Studies to evaluate whether these receptors play an important role in tumor development and may be suitable targets for therapy await the development of small molecule inhibitors to each of these receptors. In studies using endothelial integrin receptor antagonists, members of the integrin receptor family appear to be important in the growth and migration of endothelial cells during tumor induced neoangiogenesis. In preliminary experiments, endothelial integrin receptor antagonists were found to inhibit the growth of squamous cell carcinomas in vivo. Further studies will be needed to determine optimal formulation, dose and route as well as toxicity before use in clinical trials may be undertaken.